Catalent (CTLT) Receives Price Target

Catalent (CTLT) : 5 Wall Street analysts covering Catalent (CTLT) believe that the average level the stock could reach for the short term is $26.5. The maximum price target given is $31 and the minimum target for short term is around $23, hence the standard deviation is calculated at $2.87.

Catalent (CTLT) : 8 analysts are covering Catalent (CTLT) and their average rating on the stock is 2.25, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Also, Equity Analysts at the Wells Fargo upgrades the rating on Catalent (NYSE:CTLT). The brokerage firm has issued a Outperform rating on the shares. The shares were previously rated Market Perform. The rating by the firm was issued on June 21, 2016.

Catalent (NYSE:CTLT): The stock was completely flat for the day, closing at $25.23 on Thursday. The flat closing masks the intraday volatility in the stock. After opening at $25.15, the stock touched an intraday high of $25.62 and a low of $24.90. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $25.23. The total trading volume on Thursday was 711,891.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.